Laboratory Medicine ›› 2023, Vol. 38 ›› Issue (7): 659-664.DOI: 10.3969/j.issn.1673-8640.2023.07.008
Previous Articles Next Articles
Received:2022-05-24
Revised:2022-12-30
Online:2023-07-30
Published:2023-09-18
CLC Number:
MA Jianguo, LI Hongchun. Correlation between blood lipid levels and cardiac function indexes in patients with coronary heart disease[J]. Laboratory Medicine, 2023, 38(7): 659-664.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2023.07.008
| 组别 | 例数 | TG/(mmol/L) | LDL-C/(mmol/L) | HDL-C/(mmol/L) | sd-LDL-C/(mmol/L) | TC/(mmol/L) |
|---|---|---|---|---|---|---|
| CHD组 | 200 | 1.73±0.76* | 2.45±0.51* | 1.13±0.26* | 1.16±0.21 | 4.73±1.26* |
| 男性 | 78 | 1.72±0.75# | 2.39±0.49# | 1.14±0.25# | 1.15±0.19 | 4.66±1.11# |
| 女性 | 122 | 1.73±0.76△ | 2.48±0.51△ | 1.13±0.26△ | 1.17±0.22 | 4.80±1.24△ |
| 对照组 | 200 | 1.65±0.67 | 2.14±0.42 | 1.25±0.32 | 1.12±0.17 | 3.32±1.17 |
| 男性 | 79 | 1.65±0.66 | 2.11±0.40 | 1.27±0.29 | 1.12±0.16 | 3.20±1.18 |
| 女性 | 121 | 1.66±0.67 | 2.16±0.41 | 1.24±0.33 | 1.12±0.18 | 3.35±1.11 |
| 组别 | apo A/(g/L) | apo B/(g/L) | apo E/(mg/L) | Lp(a)/(mg/L) | Lp-PLA2/(pg/mL) | |
| CHD组 | 1.31±0.35* | 0.98±0.26* | 54.44±17.49* | 29.86±5.37* | 235.62±69.35* | |
| 男性 | 1.32±0.36# | 1.01±0.24# | 53.25±17.11# | 30.05±5.01# | 211.09±58.29# | |
| 女性 | 1.30±0.33△ | 0.97±0.27△ | 55.01±17.84△ | 29.11±5.43△ | 241.22±71.33△ | |
| 对照组 | 1.59±0.37 | 0.83±0.21 | 32.55±6.49 | 21.42±6.53 | 153.22±43.15 | |
| 男性 | 1.59±0.35 | 0.83±0.19 | 30.56±5.62 | 21.77±6.11 | 149.50±38.55 | |
| 女性 | 1.58±0.38 | 0.82±0.22 | 32.88±6.66 | 21.31±6.42 | 155.90±43.59 |
| 组别 | 例数 | TG/(mmol/L) | LDL-C/(mmol/L) | HDL-C/(mmol/L) | sd-LDL-C/(mmol/L) | TC/(mmol/L) |
|---|---|---|---|---|---|---|
| CHD组 | 200 | 1.73±0.76* | 2.45±0.51* | 1.13±0.26* | 1.16±0.21 | 4.73±1.26* |
| 男性 | 78 | 1.72±0.75# | 2.39±0.49# | 1.14±0.25# | 1.15±0.19 | 4.66±1.11# |
| 女性 | 122 | 1.73±0.76△ | 2.48±0.51△ | 1.13±0.26△ | 1.17±0.22 | 4.80±1.24△ |
| 对照组 | 200 | 1.65±0.67 | 2.14±0.42 | 1.25±0.32 | 1.12±0.17 | 3.32±1.17 |
| 男性 | 79 | 1.65±0.66 | 2.11±0.40 | 1.27±0.29 | 1.12±0.16 | 3.20±1.18 |
| 女性 | 121 | 1.66±0.67 | 2.16±0.41 | 1.24±0.33 | 1.12±0.18 | 3.35±1.11 |
| 组别 | apo A/(g/L) | apo B/(g/L) | apo E/(mg/L) | Lp(a)/(mg/L) | Lp-PLA2/(pg/mL) | |
| CHD组 | 1.31±0.35* | 0.98±0.26* | 54.44±17.49* | 29.86±5.37* | 235.62±69.35* | |
| 男性 | 1.32±0.36# | 1.01±0.24# | 53.25±17.11# | 30.05±5.01# | 211.09±58.29# | |
| 女性 | 1.30±0.33△ | 0.97±0.27△ | 55.01±17.84△ | 29.11±5.43△ | 241.22±71.33△ | |
| 对照组 | 1.59±0.37 | 0.83±0.21 | 32.55±6.49 | 21.42±6.53 | 153.22±43.15 | |
| 男性 | 1.59±0.35 | 0.83±0.19 | 30.56±5.62 | 21.77±6.11 | 149.50±38.55 | |
| 女性 | 1.58±0.38 | 0.82±0.22 | 32.88±6.66 | 21.31±6.42 | 155.90±43.59 |
| 组别 | 例数 | EDV/mm | ESV/mm | LVEF/% |
|---|---|---|---|---|
| CHD组 | 200 | 49.35±3.78* | 37.85±2.16* | 57.52±6.81* |
| 男性 | 78 | 48.66±2.87# | 37.44±2.22# | 58.22±7.01# |
| 女性 | 122 | 49.75±3.82△ | 38.02±2.26△ | 57.31±6.70△ |
| 对照组 | 200 | 45.19±3.53 | 30.25±2.27 | 65.51±2.95 |
| 男性 | 79 | 44.65±3.51 | 29.88±2.21 | 64.41±3.11 |
| 女性 | 121 | 45.76±3.67 | 30.51±2.30 | 65.77±2.78 |
| 组别 | 例数 | EDV/mm | ESV/mm | LVEF/% |
|---|---|---|---|---|
| CHD组 | 200 | 49.35±3.78* | 37.85±2.16* | 57.52±6.81* |
| 男性 | 78 | 48.66±2.87# | 37.44±2.22# | 58.22±7.01# |
| 女性 | 122 | 49.75±3.82△ | 38.02±2.26△ | 57.31±6.70△ |
| 对照组 | 200 | 45.19±3.53 | 30.25±2.27 | 65.51±2.95 |
| 男性 | 79 | 44.65±3.51 | 29.88±2.21 | 64.41±3.11 |
| 女性 | 121 | 45.76±3.67 | 30.51±2.30 | 65.77±2.78 |
| 指标 | EDV | ESV | LVEF | |||||
|---|---|---|---|---|---|---|---|---|
| r值 | P值 | r值 | P值 | r值 | P值 | |||
| TG | 0.582 | <0.001 | 0.524 | <0.001 | -0.625 | <0.001 | ||
| LDL-C | 0.626 | <0.001 | 0.593 | <0.001 | -0.573 | <0.001 | ||
| HDL-C | -0.566 | <0.001 | -0.621 | <0.001 | 0.546 | <0.001 | ||
| TC | 0.771 | <0.001 | 0.726 | <0.001 | -0.635 | <0.001 | ||
| apo A | -0.623 | <0.001 | -0.526 | <0.001 | 0.658 | <0.001 | ||
| apo B | 0.632 | <0.001 | 0.711 | <0.001 | -0.578 | <0.001 | ||
| apo E | 0.593 | <0.001 | 0.726 | <0.001 | -0.633 | <0.001 | ||
| Lp(a) | 0.668 | <0.001 | 0.692 | <0.001 | -0.627 | <0.001 | ||
| Lp-PLA2 | 0.591 | <0.001 | 0.623 | <0.001 | -0.663 | <0.001 | ||
| 指标 | EDV | ESV | LVEF | |||||
|---|---|---|---|---|---|---|---|---|
| r值 | P值 | r值 | P值 | r值 | P值 | |||
| TG | 0.582 | <0.001 | 0.524 | <0.001 | -0.625 | <0.001 | ||
| LDL-C | 0.626 | <0.001 | 0.593 | <0.001 | -0.573 | <0.001 | ||
| HDL-C | -0.566 | <0.001 | -0.621 | <0.001 | 0.546 | <0.001 | ||
| TC | 0.771 | <0.001 | 0.726 | <0.001 | -0.635 | <0.001 | ||
| apo A | -0.623 | <0.001 | -0.526 | <0.001 | 0.658 | <0.001 | ||
| apo B | 0.632 | <0.001 | 0.711 | <0.001 | -0.578 | <0.001 | ||
| apo E | 0.593 | <0.001 | 0.726 | <0.001 | -0.633 | <0.001 | ||
| Lp(a) | 0.668 | <0.001 | 0.692 | <0.001 | -0.627 | <0.001 | ||
| Lp-PLA2 | 0.591 | <0.001 | 0.623 | <0.001 | -0.663 | <0.001 | ||
| 组别 | 例数 | EDV/mm | ESV/mm | LVEF/% |
|---|---|---|---|---|
| LDL-C≤3.40 mmol/L组 | 146 | 47.35±3.70 | 36.85±1.90 | 59.02±6.61 |
| LDL-C >3.40 mmol/L组 | 54 | 52.50±3.55 | 39.10±2.15 | 54.43±5.90 |
| t值 | 15.230 | 13.500 | 18.300 | |
| P值 | <0.001 | <0.001 | <0.001 |
| 组别 | 例数 | EDV/mm | ESV/mm | LVEF/% |
|---|---|---|---|---|
| LDL-C≤3.40 mmol/L组 | 146 | 47.35±3.70 | 36.85±1.90 | 59.02±6.61 |
| LDL-C >3.40 mmol/L组 | 54 | 52.50±3.55 | 39.10±2.15 | 54.43±5.90 |
| t值 | 15.230 | 13.500 | 18.300 | |
| P值 | <0.001 | <0.001 | <0.001 |
| 组别 | 例数 | EDV/mm | ESV/mm | LVEF/% |
|---|---|---|---|---|
| TC≤5.17 mmol/L组 | 110 | 46.70±3.45 | 36.48±2.01 | 60.02±6.50 |
| TC>5.17 mmol/L组 | 90 | 63.05±3.55 | 39.96±2.10 | 54.04±5.80 |
| t值 | 18.200 | 16.280 | 20.050 | |
| P值 | <0.001 | <0.001 | <0.001 |
| 组别 | 例数 | EDV/mm | ESV/mm | LVEF/% |
|---|---|---|---|---|
| TC≤5.17 mmol/L组 | 110 | 46.70±3.45 | 36.48±2.01 | 60.02±6.50 |
| TC>5.17 mmol/L组 | 90 | 63.05±3.55 | 39.96±2.10 | 54.04±5.80 |
| t值 | 18.200 | 16.280 | 20.050 | |
| P值 | <0.001 | <0.001 | <0.001 |
| 项目 | EDV | ||||
|---|---|---|---|---|---|
| β值 | 标准误 | Wald值 | P值 | OR值(95%CI) | |
| 单因素分析 | |||||
| LDL-C(≤3.40 mmol/L与>3.40 mmol/L) | 0.255 | 0.012 | 13.10 | <0.001 | 2.150(1.010~3.225) |
| TC(≤5.17 mmol/L与>5.17 mmol/L) | 0.271 | 0.105 | 8.650 | <0.001 | 2.289(1.280~3.405) |
| 多因素分析① | |||||
| LDL-C(≤3.40 mmol/L与>3.40 mmol/L) | 0.101 | 0.007 | 4.30 | <0.001 | 2.020(1.009~3.880) |
| TC(≤5.17 mmol/L与>5.17 mmol/L) | 0.088 | 0.075 | 3.040 | <0.001 | 1.985(1.030~3.875) |
| 项目 | ESV | ||||
| β值 | 标准误 | Wald值 | P值 | OR值(95%CI) | |
| 单因素分析 | |||||
| LDL-C(≤3.40 mmol/L与>3.40 mmol/L) | 0.127 | 0.091 | 6.345 | <0.001 | 1.850(1.025~2.660) |
| TC(≤5.17 mmol/L与>5.17 mmol/L) | 0.118 | 0.170 | 8.95 | <0.001 | 2.119(1.015~3.815) |
| 多因素分析① | |||||
| LDL-C(≤3.40 mmol/L与>3.40 mmol/L) | 0.077 | 0.067 | 4.785 | <0.001 | 1.746(1.005~2.800) |
| TC(≤5.17 mmol/L与>5.17 mmol/L) | 0.108 | 0.110 | 3.08 | <0.001 | 1.973(1.009~4.010) |
| 项目 | LVEF | ||||
| β值 | 标准误 | Wald值 | P值 | OR值(95%CI) | |
| 单因素分析 | |||||
| LDL-C(≤3.40 mmol/L与>3.40 mmol/L) | -0.669 | 0.025 | 8.60 | <0.001 | 1.980(1.220~3.005) |
| TC(≤5.17 mmol/L与>5.17 mmol/L) | -0.725 | 0.041 | 4.300 | <0.001 | 1.681(1.105~2.335) |
| 多因素分析① | |||||
| LDL-C(≤3.40 mmol/L与>3.40 mmol/L) | -0.300 | 0.045 | 4.555 | <0.001 | 1.666(1.122~2.144) |
| TC(≤5.17 mmol/L与>5.17 mmol/L) | -0.305 | 0.040 | 5.035 | <0.001 | 1.585(1.110~2.146) |
| 项目 | EDV | ||||
|---|---|---|---|---|---|
| β值 | 标准误 | Wald值 | P值 | OR值(95%CI) | |
| 单因素分析 | |||||
| LDL-C(≤3.40 mmol/L与>3.40 mmol/L) | 0.255 | 0.012 | 13.10 | <0.001 | 2.150(1.010~3.225) |
| TC(≤5.17 mmol/L与>5.17 mmol/L) | 0.271 | 0.105 | 8.650 | <0.001 | 2.289(1.280~3.405) |
| 多因素分析① | |||||
| LDL-C(≤3.40 mmol/L与>3.40 mmol/L) | 0.101 | 0.007 | 4.30 | <0.001 | 2.020(1.009~3.880) |
| TC(≤5.17 mmol/L与>5.17 mmol/L) | 0.088 | 0.075 | 3.040 | <0.001 | 1.985(1.030~3.875) |
| 项目 | ESV | ||||
| β值 | 标准误 | Wald值 | P值 | OR值(95%CI) | |
| 单因素分析 | |||||
| LDL-C(≤3.40 mmol/L与>3.40 mmol/L) | 0.127 | 0.091 | 6.345 | <0.001 | 1.850(1.025~2.660) |
| TC(≤5.17 mmol/L与>5.17 mmol/L) | 0.118 | 0.170 | 8.95 | <0.001 | 2.119(1.015~3.815) |
| 多因素分析① | |||||
| LDL-C(≤3.40 mmol/L与>3.40 mmol/L) | 0.077 | 0.067 | 4.785 | <0.001 | 1.746(1.005~2.800) |
| TC(≤5.17 mmol/L与>5.17 mmol/L) | 0.108 | 0.110 | 3.08 | <0.001 | 1.973(1.009~4.010) |
| 项目 | LVEF | ||||
| β值 | 标准误 | Wald值 | P值 | OR值(95%CI) | |
| 单因素分析 | |||||
| LDL-C(≤3.40 mmol/L与>3.40 mmol/L) | -0.669 | 0.025 | 8.60 | <0.001 | 1.980(1.220~3.005) |
| TC(≤5.17 mmol/L与>5.17 mmol/L) | -0.725 | 0.041 | 4.300 | <0.001 | 1.681(1.105~2.335) |
| 多因素分析① | |||||
| LDL-C(≤3.40 mmol/L与>3.40 mmol/L) | -0.300 | 0.045 | 4.555 | <0.001 | 1.666(1.122~2.144) |
| TC(≤5.17 mmol/L与>5.17 mmol/L) | -0.305 | 0.040 | 5.035 | <0.001 | 1.585(1.110~2.146) |
| [1] |
GBD 2016 Causes of Death Collaborators. Global,regional,and national age-sex specific mortality for 264 causes of death,1980-2016:a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet,2017, 390(10100):1151-1210.
DOI URL |
| [2] | 《中国心血管病报告2017》概要[J]. 中国循环杂志, 2018, 33(1):1-8. |
| [3] | 黄曼萍, 梁东辉, 刘永源, 等. 高密度脂蛋白在不同证型冠心病患者血清中的表达及意义[J]. 广东医学, 2015, 36(21):3395-3398. |
| [4] |
MARBER M. The future of myocardial injury biomarkers in cardiovascular disease:looking beyond cardiac troponins[J]. Cardiovasc Res, 2018, 114(6):e39-e40.
DOI URL |
| [5] | 王志剑, 邓之敏, 李雪华, 等. 人血浆脂蛋白相关磷脂酶A2与冠心病合并糖尿病及高血压的相关性研究[J]. 临床检验杂志(电子版), 2018, 7(2):203-205. |
| [6] |
FIHN S D, BLANKENSHIP J C, ALEXANDER K P, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,and the American Association for Thoracic Surgery,Preventive Cardiovascular Nurses Association,Society for Cardiovascular Angiography and Interventions,and Society of Thoracic Surgeons[J]. J Am Coll Cardiol,2014, 64(18):1929-1949.
DOI URL |
| [7] | 中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版)[J]. 中国循环杂志, 2016, 31(10):937-950. |
| [8] | 杨林, 葛百平, 姜珊, 等. TG/HDL-C比值与冠心病患者致病风险的关系及诊断价值[J]. 中国医药导报, 2021, 18(11):66-69. |
| [9] | 王黎, 韩泉, 谢丹. 血清胱抑素C、同型半胱氨酸、甘油三酯/高密度脂蛋白胆固醇比值联合检测对老年冠心病的诊断价值[J]. 临床和实验医学杂志, 2021, 20(9):931-934. |
| [10] | 段厚全, 王鹤. LDL-C、LP-a与Hcy联合检测在冠心病诊治中的应用[J]. 海南医学, 2015,(10):1463-1465. |
| [11] | 胡晓蔚, 孙建琦, 章锡林, 等. 载脂蛋白A-1及高密度脂蛋白在冠心病中作用的比较[J]. 皖南医学院学报, 2019, 38(1):60-63. |
| [12] | LI J, CHEN L L, WANG J G, et al. Association between apolipoprotein E gene and heart blood stasis syndrome in premature coronary heart disease pedigrees within the hunan han nation population[J]. Biomed Res, 2017, 28(21):9543-9548. |
| [13] | 张爱爱, 韩伟, 宋建英, 等. 血浆脂蛋白相关磷脂酶A2浓度与不同类型冠心病相关性研究[J]. 心肺血管病杂志, 2020, 39(2):139-142. |
| [14] | 李春晖. 福辛普利联合美托洛尔治疗冠心病心力衰竭的临床效果观察[J]. 河南医学研究, 2016, 25(2):302. |
| [15] | 周依蒙, 郑鹏翔, 陈德, 等. 冠心病合并心力衰竭患者血清Cat S、Periostin、NT-proBNP水平与心功能指标、炎症因子的关系研究[J]. 国际检验医学杂志, 2021, 42(3):270-273. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
